Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effisayil 2
2018-003081-14Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of spesolimab in generalized pustular psoriasis (GPP) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Time to first generalized pustular psoriasis flare up to week 48. Started Dec 2019; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on 2018-003081-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003081-14.